CancerNCT01370980
Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
An observational study of Cancer, run by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland at 1 site in Switzerland.
Trial summary
The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- Type of treatment
- Pill or oral medicine
- How many people
- 43 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jul 2010to Sep 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.
Who may be able to join
- 18 years and older
- Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
- French speaking
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV
Lausanne, Canton of Vaud, 1010
About this study
Official title: Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.
Read the detailed description
80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).
- Conditions
- Cancer
- Keywords
- Medication Adherence, Patient Compliance, Patient Acceptance of Health Care, Administration, Oral, Cancer, Letrozol, Exemestan, Imatinib, Sunitinib, Nilotinib, Everolimus, Deferasirox
- Medical subject headings
- Neoplasms, Medication Adherence, Patient Compliance, Patient Acceptance of Health Care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Study population | Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Medication adherence
MEMS data, completed by informations given in motivational interviewing
Measured: 3 months, 6 months, 9 months, 12 months
Secondary outcomes (4)
Program implementation
Evaluating the implementation of the program in pharmacies
Measured: 1 year
Oncologists, nurses, pharmacists and patients satisfaction
By questionnaire and interviews
Measured: 1 year
Effect of Adverse Drug Reaction (ADR) on medication adherence
By MEMS data and motivational interviewing informations
Measured: 1 year
Change in Adverse Drug Reaction (ADR)
To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.
Measured: 3 months, 6 months, 9 months, 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2011 (estimated)
- Study startJul 2010
- Primary completionDec 2011
- Study completionSep 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Hospitalier Universitaire Vaudois
- Responsible party
- Sponsor
- Investigators
- Bugnon Olivier, Professor, Study chair, Center for Primary Care and Public Health (Unisante), University of Lausanne, SwitzerlandLüthi François, Dr, Study chair, Clinique Bois-Cerf, LausanneSchneider Marie-Paule, PhD, Principal investigator, Policlinique Medicale UniversitaireChevaux Bernard, Dr, Principal investigator, Centre Hospitalier Universitaire VaudoisTroxler Stéphanie, PhD Student, Principal investigator, Policlinique Medicale UniversitaireLeila Achtari, MD, Principal investigator, Centre Hospitalier Univeristaire Vaudois
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01370980
- Sponsor's protocol ID
- 139/10
- Status last verified
- Jul 2026
- First submitted
- 3 Jun 2011
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
- ClinicalTrials.gov ID
- NCT01370980
- Acronym / sponsor ID
- 139/10
- Conditions
- Cancer
- Keywords
- Medication Adherence, Patient Compliance, Patient Acceptance of Health Care, Administration, Oral, Cancer, Letrozol, Exemestan, Imatinib
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Center for Primary Care and Public Health (Unisante), University of Lausanne, SwitzerlandUniversity, hospital or other
- Collaborators
- Centre Hospitalier Universitaire Vaudois
- Study start
- Jul 2010
- Primary completion
- Dec 2011 (actual)
- Study completion
- Sep 2014 (actual)
- First posted
- 10 Jun 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.
Detailed description
80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study population | – | –Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.
Key inclusion criteria (3 listed)
- 18 years and older
- Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
- French speaking
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Medication adherence
Time frame: 3 months, 6 months, 9 months, 12 months
MEMS data, completed by informations given in motivational interviewing
4 secondary outcomes
Program implementation
Time frame: 1 year
Oncologists, nurses, pharmacists and patients satisfaction
Time frame: 1 year
Effect of Adverse Drug Reaction (ADR) on medication adherence
Time frame: 1 year
Change in Adverse Drug Reaction (ADR)
Time frame: 3 months, 6 months, 9 months, 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bugnon Olivier, Professor study chair
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Lüthi François, Dr study chair
Clinique Bois-Cerf, Lausanne
Schneider Marie-Paule, PhD principal investigator
Policlinique Medicale Universitaire
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Medication adherence (time frame: 3 months, 6 months, 9 months, 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.